Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• EphA2 receptor tyrosine kinase is overexpressed in malignant cells, presenting a therapeutic target.
• Bispecific antibody technology offers a strategy for redirecting immune cells to target cancer.

Purpose of the Study:

• To develop and characterize a novel bispecific single-chain antibody (bscAb) targeting EphA2 on tumor cells and CD3 on T cells.
• To evaluate the efficacy and selectivity of the bscAb in redirecting T cells for cancer cell lysis.

Main Methods:

• Development of a bispecific single-chain antibody (bscEphA2xCD3) by fusing EphA2-specific and CD3-specific antibody fragments.
• In vitro and in vivo studies using human T cells and EphA2-expressing tumor cells, including xenograft mouse models.
• Time-lapsed microscopy to observe T cell-mediated cytotoxicity.

Main Results:

• The bscEphA2xCD3 effectively redirected unstimulated human T cells to lyse EphA2-expressing tumor cells in vitro and in vivo.
• Efficient tumor cell lysis was observed at low drug concentrations (
• The bscAb demonstrated selectivity, targeting malignant cells while sparing non-transformed EphA2-positive cells unless the target epitope was exposed.

Conclusions:

• EphA2-specific bscAb molecules are potent therapeutics with selectivity for tumor cells.
• This approach offers a promising strategy for redirecting cytotoxic T cell activity towards tumors expressing selectively accessible epitopes.